A good rule of thumb is to not invest any money with less than a two-year time horizon. The markets can be be very unpredictable in the short term–as we’ve seen so far this summer! The Fed is meeting in Jackson Hole this week to discuss the US economy, unemployment and inflation/deflation. The market will remain somewhat tumultuous until it …
Should we panic during market turmoil?
Since my retirement from practicing medicine at the end of June, you may have noticed that the stock, bond and foreign exchange (FX) markets have been tumultuous, to say the least. As both my clients and personal friends I hope that you are not surprised to learn that short-term market turbulence, caused by each new worry of the day, does …
Vailshire Results Ahead of the Pack
2015 First Quarter results are in! “Hedge funds were up 0.46% in March, according to the Barclay Hedge Fund Index compiled by BarclayHedge. The Index is up 2.57% through the end of the first quarter, versus a return of 0.95% for the S&P 500.” In a turbulent, sideways market, these are respectable results from any fund designed to preserve and …
Gilead Sciences: A Coiled Spring.
If you study the following chart, courtesy of Gurufocus.com, you will notice that Gilead Sciences (NASDAQ: GILD) has been stuck in a sideways trading pattern since August 2014. This is unfortunate news for the impatient speculator, but great news for the patient long-haul investor. Let me explain… At Vailshire Capital Management, LLC, we believe that owners of equities should consider …
Is a SEP-IRA right for your small business?
A SEP-IRA is a flexible, convenient, and affordable way for Colorado business owners to contribute to their own and to their employees’ retirement savings. What is a SEP-IRA? A Simplified Employee Pension Plan, commonly known as a SEP-IRA, is a retirement plan specifically designed for self-employed people and small business owners. When establishing a SEP-IRA plan for your Colorado business, …
A Victory For Express Scripts and AbbVie At The Expense Of Gilead Sciences, J&J And… Oh Yeah, Patients
Summary In an unprecedented move, ESRX makes Viekira Pak the exclusive option for HCV-infected patients. Preference of healthcare providers and patients disregarded for profits of PBMs and insurance companies. This is a short term, solvable event for GILD, which remains a Strong Buy. Time will reveal who owns the superior HCV treatment. In an unprecedented move, Express Scripts Holding Co. …
Ho Ho Harvoni: Gilead Sciences Is A Gift That Should Be Under Every Investor’s Tree
Summary Whether you’re a value or a growth investor, GILD belongs in your portfolio. Gilead Sciences is at the forefront of worldwide HCV eradication with its combination tablet: Harvoni. Regardless of anticipated competition, Gilead is a rapidly growing, highly profitable and cash-gushing machine. GILD is one of my top picks to significantly outperform the S&P 500 in 2015. Investing in …
Why You Should Strongly Consider CVS Caremark After Its Impressive 2nd Quarter Earnings Report
Summary CVS reported increased Q2 net revenues of 10.7%. Adjusted EPS jumped 16.5%. Obamacare-related increased individual enrollment bodes well for CVS and its shareholders. CVS Caremark Corporation (NYSE: CVS), the largest pharmacy health care provider in the United States, boasts a market cap of $91 billion and an Enterprise Value of nearly $102 billion. Though immense, CVS continues to show …
Vailshire: An Introduction
A physician-turned-hedge fund manager…is this a joke? Not at all. In fact, 2014 marks the culmination—and the beginning—of a long-awaited dream of mine. Vailshire Partners (VP), LP, is a new low-risk, multi-strategy hedge fund that operates on the same disciplined investment principles that I have personally employed for many years. The general partner (GP) of the fund is Vailshire Capital …
Your Bonds Have Abandoned You. Now What?
At the end of the 30-year bull market in bonds, it’s no secret that 2013 has been a miserable year for Treasury holders. Even the most optimistic among fixed-income investors must admit that returns look minimal at best — and negative at worst. For persons with significant allocations in longer-term Treasuries (e.g., 10 to 30 years), inflation promises to wreak …